POPULARITY
Send us a textBill Taranto is President of the Merck Global Health Innovation Fund ( MGHIF - https://www.msdghifund.com/ ).The Merck Global Health Innovation Fund was established in late 2010 as a strategic response to the challenges surrounding Merck's core business of discovering, developing and marketing innovative drugs and vaccines.Bill has more than three decades of experience in the healthcare industry. MGHIF is a $750m evergreen fund focused on identifying opportunities that are adjacent to Merck's core business of pharmaceuticals and vaccines. Under Bill's leadership, MGHIF has invested more than $1bn in 70 companies, with more than $7bn in exits.Prior to joining Merck, Bill spent 18 years at Johnson & Johnson (J&J) in various roles. As VP of healthcare strategy and venture at J&J, he was responsible for evaluating and creating new healthcare business models through venture capital and acquisitions. Prior to joining J&J, Bill spent eight years in investment banking.#BillTaranto #MerckGlobalHealthInnovationFund #Scale #Impact #InvestmentBanking #DrugDiscovery #ClinicalDevelopment #Manufacturing #SupplyChain #RealWorldEvidence #CorporateVentureCapital #STEM #Innovation #Science #Technology #Research #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcastSupport the show
In this episode of Tech Bytes, host Dan Hafner delves into the Trump administration's ambitious AI action plan aimed at securing US global leadership. Discover how this comprehensive strategy seeks to accelerate innovation, expand AI infrastructure, and enhance international leadership, all while addressing regulatory challenges and prioritizing AI education. Join us as we explore the implications of this bold move and its potential to reshape the global AI landscape. Tune in for an insightful discussion on the future of AI and its role in maintaining US economic and military superiority. #AI #USLeadership #Innovation
This is the latest episode of the free DDW narrated podcast, titled “Innovative applications of AI in drug discovery”, which covers two articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Decoding diseases: The AI renaissance in clinical trials” and “Advancing antibody discovery with AI”. In the first article, Deepika Khedekar, Associate Centralized Clinical Lead at IQVIA, explains how artificial intelligence could make clinical trials more accurate, accessible and standardised. In the second article, DDW Editor Reece Armstrong, speaks to Kashif Sadiq, Founder of DenovAI Biotech about the importance of computational methods in this field.
Synopsis: What do courtroom litigation, computational biology, and fibrosis drug development have in common? In this episode of Biotech 2050, host Alok Tayi speaks with Ahmed Mousa, CEO of Vicore Pharma, to explore his unconventional journey from biotech law to the C-suite. Ahmed shares how Vicore is advancing a first-in-class therapy targeting the angiotensin II type 2 receptor to treat idiopathic pulmonary fibrosis (IPF)—a devastating disease with limited options and poor survival. The conversation dives into how AI is reshaping drug discovery, the promise of precision in early-stage candidate design, and the regulatory and data challenges biotech must overcome. Ahmed also reflects on leading a Swedish-listed biotech as an American CEO, and how a patient-first mission continues to fuel bold innovation across continents. Biography: Ahmed Mousa is the Chief Executive Officer of Vicore Pharma (VICO.ST), where he leads the company's mission to advance angiotensin II type 2 receptor agonists for the treatment of idiopathic pulmonary fibrosis and other serious diseases. Under his leadership, Vicore continues to expand its clinical pipeline and global presence in respiratory and fibrotic diseases. Previously, Ahmed served as Senior Vice President, Chief Business Officer, and General Counsel at Pieris Pharmaceuticals (PIRS). In this role, he was the site head for the company's Boston office and oversaw business development, portfolio strategy, centralized project leadership, and quality assurance. He also led Pieris' legal and intellectual property functions, including licensing, corporate governance, and management of the company's global patent portfolio. Before joining Pieris, Ahmed was an attorney at Covington & Burling LLP, where he advised pharmaceutical and biotechnology companies on a range of regulatory and intellectual property matters. He also served as a law clerk for the U.S. Court of Appeals for the Third Circuit and began his legal career as an IP associate at Kirkland & Ellis LLP. Ahmed holds dual undergraduate degrees in Molecular Biology and Government from Cornell University, a Master's in Biotechnology from Johns Hopkins University, and a J.D. with honors from Georgetown Law, where he was Editor-in-Chief of the Georgetown Journal of International Law.
In this episode of the Xtalks Life Science Podcast, Vera Kovacevic speaks with Gene Mack, CEO and President of Gain Therapeutics, a company focused on AI-driven small molecule discovery for diseases with high unmet medical needs. With over 25 years of leadership across biopharma, capital markets and corporate strategy, Gene shares his unique perspective on the intersection of artificial intelligence and drug development — and how Gain Therapeutics is using it to tackle diseases with high unmet medical need. Prior to joining Gain, Gene was CFO at Imcyse SA between 2021 and 2023, and at OncoC4, which spun out of Merck's acquisition of OncoImmune in 2020 where he had also been CFO. Gene discusses his career journey from Wall Street to the C-suite, his experience raising over $350 million in biotech funding and the exciting science behind Gain's drug discovery platform. Gene received both his Bachelor of Science in biochemistry and MBA in finance from Fordham University. Whether you're a biotech investor, drug developer or simply curious about how AI is reshaping the future of medicine, tune into the conversation. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured
In this episode, we sit down with Dr. Marschall Runge - CEO of Michigan Medicine and Dean of the University of Michigan Medical School - to explore how artificial intelligence (AI) is transforming the entire landscape of drug discovery, clinical trial design, and precision medicine.With deep insights from decades of leadership across biotechnology, genomics, and translational research, Dr. Runge shares exclusive stories on how pharmaceutical giants and biotech startups are using AI to compress years of research into days, optimize molecule design, and personalize treatments with astonishing accuracy.From protein folding to AI-generated molecules, and from digital twins to FDA-approved synthetic data in trials, this episode is a must-listen for anyone working in:Pharmaceutical innovationAI and machine learning in healthcarePrecision medicineClinical trial optimizationHealthtech entrepreneurshipBiotech investment and strategyTopics Covered In This Episode:How AI is accelerating drug discovery timelines from years to daysReal-world case studies using AI to find novel inhibitorsThe rise of digital twins, synthetic data, and AI-driven clinical trialsDemocratization of drug development for startups and biotech foundersData bias, model design, and ethical considerations in AI-driven researchPredictive accuracy of AI-designed drugs vs traditional pharma R&DThe future of personalized medicine powered by omics and machine learningThe impact of large tech companies (Google, Apple, NVIDIA) entering pharmaExciting breakthroughs in anti-aging and longevity drug researchDr. Runge's predictions for the next 10 years in healthcare and AIAbout the Podcast:AI for Pharma Growth is a podcast focused on exploring how artificial intelligence can revolutionise healthcare by addressing disparities and creating equitable systems. Join us as we unpack groundbreaking technologies, real-world applications, and expert insights to inspire a healthier, more equitable future.This show brings together leading experts and changemakers to demystify AI and show how it's being used to transform healthcare. Whether you're in the medical field, technology sector, or just curious about AI's role in social good, this podcast offers valuable insights.AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr. Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business. This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget. As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses. This podcast features many experts who have developed powerful AI powered tools that are the secret behind some time saving and supercharged revenue generating business results. Those who share their stories and expertise show how AI can be applied to sales, marketing, production, social media, psychology, customer insights and so much more. Dr. Andree Bates LinkedIn | Facebook |
Send us a textJosh Haimson is Co-Founder and CEO of Inductive Bio ( https://www.inductive.bio/about ), a technology company focused on democratizing artificial intelligence (AI) models to transform small molecule drug discovery, eliminating Absorption, Distribution, Metabolism, Excretion and Toxicology (ADMET) bottlenecks with state-of-the-art AI models and generative chemistry, powered by a unique pre-competitive data consortium.Josh has spent his career focused on the intersection of machine learning, product, and life sciences/healthcare.Prior to Inductive, Josh was the Director of Product for the ML and data curation organizations at Flatiron Health, where his teams worked to generate real-world evidence (RWE) at scale across Flatiron's network of over 2 million active cancer patients for use by researchers in pharma, academia, and government.Prior to Flatiron, Josh was at MIT studying computer science and working with researchers at Massachusetts General Hospital to use ML and NLP to predict patient response to cardiac resynchronization therapy.#JoshHaimson #InductiveBio #SmallMolecule #DrugDiscovery #Absorption #Distribution #Metabolism #Excretion #Toxicology #ADMET #AI #GenerativeChemistry #MachineLearning #CardiacResynchronizationTherapy #MolecularGlue #FlatironHealth #PreCompetitiveDataConsortium #RealWorldEvidence #RealWorldData #RWE #ArtificialIntelligence #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show
No Priors: Artificial Intelligence | Machine Learning | Technology | Startups
AI has already fueled breakthroughs in biotechnology—but now, further advances in AI are poised to fuel pharmaceutical discoveries as well. Sarah Guo sits down with Joshua Meier and Jack Dent, co-founders of Chai Discovery, whose newly launched Chai-2 designs bespoke antibodies that bind to their targets at a jaw-dropping 20% rate. Jack and Joshua talk about the implications for Chai-2's success rate at discovering antibodies for the pharmaceutical industry, how structure prediction is pivotal in making the model work, and future potential for using the model to optimize other molecular properties. Plus, they talk about what they believe bioscientists should be learning to best utilize Chai-2's technology. Sign up for new podcasts every week. Email feedback to show@no-priors.com Follow us on Twitter: @NoPriorsPod | @Saranormous | @EladGil | @_jackdent | @joshim5 Chapters: 00:00 – Joshua Meier and Jack Dent Introduction 01:09 – Genesis of Chai Discovery 06:12 – Chai-2 Model 10:13 – Criteria for Specifying Targets for Chai-2 13:12 – How the Chai-2 Model Works 16:12 – Emergent Vocabulary from Chai-2 18:15 – Hopes for Chai-2's Impact 20:33 – Reception of the Chai-2 Model 22:16 – Future of Wet Lab Screening and Biotech 27:08 – Optimizing Other Molecule Properties 31:37 – Where Chai Invests From Here 36:20 – What Bioscientists Should Learn for Chai-2 40:23 – How Jack and Josh Oriented to the Biotech Space 43:38 – Platform Investment and Chai-2 46:53 – Scaling Chai Discovery 48:21 – Hiring at Chai Discovery 49:09 – Conclusion
MONEY FM 89.3 - Prime Time with Howie Lim, Bernard Lim & Finance Presenter JP Ong
When we think about drug discovery, the words fast and efficient don’t usually come to mind - but a Singapore-based biotech startup is challenging that reality. Nanyang Biologics is harnessing the power of AI and an extensive library of tropical bioactives to accelerate how we discover new treatments, not just for humans, but for animals too. So how are they doing it? On the Right Business, Hongbin Jeong speaks to Giang Nyugen, Chief Technology Officer of Nanyang Biologics (NYB), to find out more.See omnystudio.com/listener for privacy information.
What if a mouse could help shape the future of cancer treatment? In this episode of Sounds of Science, host Mary Parker speaks with Julia Schüler, DVM, PhD, Research Director and Therapeutic Area Lead for Oncology at Charles River. Julia shares how patient-derived xenograft (PDX) models—often described as “avatars” of human tumors—are transforming preclinical oncology research. From preserving tumor heterogeneity to improving translational relevance, PDX models are accelerating the discovery of more effective, personalized therapies. Tune in as we explore how these advanced models are driving innovation across the drug development pipeline—from target discovery to clinical trial design.Show NotesPDX Tumor Organoids : A New Tool in Drug Discovery Testing Realm Organoids: Some Assembly Required Patient-Derived Xenografts- PDX Models 3D Tumor Models In Vitro PDX Assays
Joining us on this episode is Tom Neyarapally, co-founder and CEO of Archetype Therapeutics, an exciting new AI-driven company in the drug discovery space. Archetype is an AI-native biotech pioneering the use of generative chemogenomics and patient clinicogenomic data to virtually screen billions of potential drug candidates each day.TPM E47 highlights >Episode 47 links:Archetype TherapeuticsTom Neyarapally on LinkedIn “Exploring a “Patient-First” Path in Drug Discovery”, a LinkedIn article by Tom Neyarapally, Paul McDonagh, and Rafael Rosengarten
Today's guest is Annabel Romero, Specialist Leader focusing on AI for Drug Discovery at Deloitte and a structural biologist by training. Deloitte is a global consulting firm known for its work in digital transformation, data strategy, and AI adoption across regulated industries. Annabel joins Emerj Editorial Director Matthew DeMello to explore how AI systems are being designed to think more like scientists—particularly in protein modeling and life sciences research. She shares how tools like AlphaFold and large language models are accelerating drug targeting, predicting allergen cross-reactivity, and translating learnings from human biology to agricultural innovation. This episode is sponsored by Deloitte. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast!
In this episode of Breaking Health, host Steve Krupa speaks with Matt Bettonville, investor at Yosemite, about the state of oncology research and his hunt for investments in discovery and treatment tools. Bettonville delves into the key to cancer treatment, where deals are flowing towards in the market, and how the AI revolution is helping with drug discovery and cancer treatment breakthroughs. He also discusses the complications (and frustrations) of making treatments affordable, finding new targets in primary cancers most frequently seen in the population, and the importance of early detection. Links from this episode: HealthEdgeYosemite
What are the most interesting questions in biotech, and is it even possible to find answers to those questions?Alex Telford is the co-founder of Convoke and a biotech blogger from the San Francisco Bay Area. His blog post, 'Some questions about biotech that I find interesting' provoked conversations online as readers engaged with questions about topics as diverse as the impacts of regulation, the role of serendipity in drug discovery, clinical trial failure rates, and the best structure for governing large pharmaceutical companies companies.In this episode Alex explains the work he is doing at Convoke before opening the door to his insatiable curiosity about the biotech industry.01:17 Introducing Alex Telford04:28 The business of biotech09:02 Convoke and its mission14:21 ‘Some questions about biotech that I find interesting'16:57 Why founders should be writing and blogging18:44 Generating good questions about biotech20:50 AI and its role in drug discovery26:21 Will AI mean the end of serendipitous drug discovery?28:15 Regulatory challenges for biotech34:17 Is the FDA a net positive or net negative for the industry?36:56 The unanswerable questions in biotech39:00 Digital twins in biotechnology42:15 The next interesting questions in biotechInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: 12 AI drug discovery companies you should know aboutDoes the FDA need to tighten its grip on drug trials in the U.S.?2025 predictions: Which trends are set to shape the biotech industry this year?
This is the latest episode of the free DDW narrated podcast, titled “Innovative uses for biomarkers in drug discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Advances in neuroscience drug discovery”, “Putting human data at the centre of drug discovery”, and “The era of precision neuroscience”. In the first article, Lu Rahman looks at neuroscience drug discovery – advances and challenges – and how breakthroughs in this field are helping address areas of unmet need. In the second article, James Peach, Co-Founder and CEO of Human Centric Drug Discovery (HCDD), an Oxford University spin-out improving neurology drug discovery by bringing more human data to the process, shares insight with me. In the third article, Dr Steve Gardner, CEO of the computational biology company PrecisionLife, explores the challenges of achieving precision medicine in complex CNS conditions and explains how new precision neuroscience approaches are benefitting pharmaceutical companies who are again investing in the field to develop better treatments for neurological and neuropsychiatric diseases.
On today's show we're excited to welcome Rick Peng, the Innovation Hub Manager and Digital Licensing Professional at Memorial Sloan Kettering Cancer Center. We talk about how your organization can build an outside-in, external innovation program to deliver outsized results. Rick breaks down the secret sauce of the MSK Innovation Hub, an accelerator program designed to encourage collaborations between Memorial Sloan Kettering Cancer Center and digital health companies, focused on the diagnosis, treatment, and care of cancer patients. We discuss their new Innovation Hub Challenge focused on AI Drug Discovery – and why the access to data sets, is a key unlock for ai driven solutions.
Origins - A podcast about Limited Partners, created by Notation Capital
Zach Weinberg, co-founder and CEO of Curie.Bio, is redefining early-stage biotech investing with an operator's mindset and a founder-first philosophy. His approach combines funding with operational support and direct access to world-class drug hunters to dramatically increase odds of success. Today, Zach sits down with Nick Chirls, GP at Asylum Ventures and Beezer Clarkson, LP at Sapphire Partners to discuss the massive risk associated with traditional therapeutics startups, how pairing a drug discovery partner with a seed investor solves those inefficiencies, and how biotech, the global economy and the political landscape are all closely connected.Learn more about Sapphire Partners: sapphireventures.com/sapphire-partnersLearn more about OpenLP: openlp.vcLearn more about Asylum Ventures: asylum.vcLearn more about Curie.Bio: curie.bioFor a monthly roundup of the latest venture insights, including the newest Origins episodes, subscribe to the OpenLP newsletter – delivered straight to your inbox: subscribe.openlp.vcCHAPTERS:(0:00) Welcome to Origins(5:08) Was Hunter High School Harder Than Penn?(10:22) Transitioning From SaaS to Biotech(20:55) Why Is Building a Biotech Venture Firm So Hard?(27:55) Building Curie.Bio(32:24) Zach on Drug Discovery(43:12) Biotech in China(49:42) AI in Biotech(54:51) "The Manhattan Project of Biology"
In our next episode, we're joined by Jason Cole, a Senior Research Fellow at the Cambridge Crystallographic Data Center (CCDC). He shares his fascinating journey, starting from his childhood in Italy, where his love for science blossomed, all the way to his impressive career in computational chemistry and crystallography. We chat about what CCDC does in terms of gathering and sharing crystallographic data, the ups and downs of software development in this field, and why it's so crucial to validate docking software. Jason also highlights the importance of data standards, the philanthropic mission of CCDC, and what the future holds for drug discovery, particularly with the exciting possibilities of artificial intelligence (AI) and quantum computing. It's a great conversation packed with insights!
This is the latest episode of the free DDW narrated podcast, titled “Innovative uses for biomarkers in drug discovery”, which covers two articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “How biomarkers can help discover new treatments for women's health” and “Could NfL accelerate drug development for neurodegenerative diseases?” In the first article, DDW Editor Reece Armstrong speaks to Dr Steve Gardner, Co-Founder and CEO of PrecisionLife about work the company is doing to improve our understanding of endometriosis. In the second article, Professor Andy Whiting and Dr Tony Lockett discuss how specific levels of a protein could be used to advance drug development in neurodegenerative diseases.
Watch the video version of this podcast episode.https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-167-with-tom-sakmar-%26-ilana-kotliar---------------------------------Become a #DrGPCR Ecosystem Member---------------------------------Imagine a world in which the vast majority of us are healthy.The #DrGPCR Ecosystem is all about dynamic interactions between us working towards exploiting the druggability of #GPCRs. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together.---------------------------------To build our #GPCR Ecosystem, we created various enabling outlets.Premium YearlyPremium Yearly for TeamsDeveloping CountriesAre you a #GPCR professional?Subscribe to the Classified GPCR Weekly NewsListen and subscribe to #DrGPCRPodcast
Simply Wall St Market Insights for the week ending 25th May 2025.To read the full article:
Welcome back to Impact Theory with Tom Bilyeu. In this episode, I sit down with my co-host Drew to rip into one of the most turbulent weeks in global politics and economics we've seen in a long time. We break down not just the moves, but the motives and the possible massive consequences behind Trump's high-octane foreign policy—from slashing tariffs with China and locking in a colossal Saudi investment deal, to taking the unprecedented step of targeting Big Pharma with an executive order to lower drug prices. We get into whether all this fast action is actually helping America or just stirring up more chaos. Are we leveraging our moment, or just getting played by the likes of Xi and Putin? Does tough talk and bold negotiating end with real results for America, or are we setting ourselves up for long-term headaches, especially with midterms on the horizon? Then we peel back the layers on some of the rawest culture war issues, from immigration crackdowns in the UK, the controversy about a Muslim-majority city in Texas, to the viral video of world leaders acting out-of-pocket on a train to Kiev. SHOWNOTES 00:00 – China's 90-Day Tariff Pause: Progress or a Lifeline for Xi? 01:42 – Negotiation Tactics: Deal-Making or Getting Played? 03:48 – The Real Purpose of the 90-Day Pause 05:16 – China Can Print Money: Central Banks and Sinister Power 07:13 – Trump's Aggressive Approach: Productive Chaos? 09:14 – What's Actually Getting Done—And What's Just PR? 10:57 – Accepting a Gold-Plated Jet: Smart Move or Trojan Horse? 13:29 – Why “Greedy Capitalist” Isn't Always an Insult 15:51 – When Deals Cross the Line 18:38 – Global Trade Rebalancing: Is Win-Win Possible with China? 21:17 – Breaking Down the $600 Billion Saudi Deal 24:23 – Why Innovation Stalled—and What Competition With China Could Spark 25:54 – Instilling Inspiration vs. Self-Loathing in American Youth 29:31 – Price Fixing Big Pharma: Popular, but Ultimately Dangerous? 32:15 – Central Banks: The Fungus Beneath the Free Market 36:07 – How Drug Pricing Actually Gets Decided (and Where It Breaks Down) 39:04 – Why Price Fixing Backfires 42:36 – Cigarettes, Prisons, and the True Nature of Supply & Demand 47:14 – Drug Discovery, Innovation, and Unintended Consequences 54:58 – Culture Wars: Immigration Policy in the UK and the US 58:34 – Building the Modern Middle East—Without Western Intervention 60:48 – The Harsh Realities of Assimilation and Cultural Conflict 65:35 – What Happens When Zoning and Religion Collide? 71:19 – Demographics as Destiny: What History Teaches About Outnumbering 74:00 – Respecting Law, Freedom, and What It Means to Be American CHECK OUT OUR SPONSORS ButcherBox: Ready to level up your meals? Go to https://ButcherBox.com/impact to get $20 off your first box and FREE bacon for life with the Bilyeu Box! Vital Proteins: Get 20% off by going to https://www.vitalproteins.com and entering promo code IMPACT at check out Shopify: Sign up for your one-dollar-per-month trial period at https://shopify.com/impact Netsuite: Download the CFO's Guide to AI and Machine Learning at https://NetSuite.com/THEORY iTrust Capital: Use code IMPACTGO when you sign up and fund your account to get a $100 bonus at https://www.itrustcapital.com/tombilyeu Mint Mobile: If you like your money, Mint Mobile is for you. Shop plans at https://mintmobile.com/impact. DISCLAIMER: Upfront payment of $45 for 3-month 5 gigabyte plan required (equivalent to $15/mo.). New customer offer for first 3 months only, then full-price plan options available. Taxes & fees extra. See MINT MOBILE for details. Learn more about your ad choices. Visit megaphone.fm/adchoices
This is the latest episode of the free DDW narrated podcast, titled “Cutting-edge tools shaping early-stage drug discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “The use-case for NGS”, “Are organ-chips the future of preclinical research?” and “What spatial biology can tell us about disease and drug discovery”. In the first article, DDW Editor Reece Armstrong speaks to Dr Darrell Green, Lecturer in RNA Biology, Biomedical Research Centre, Norwich Medical School University of East Anglia, about his work using next generation sequencing (NGS) and the areas the technology is impacting within drug discovery and development. In the second article, Diana Spencer catches up with Lorna Ewart, PhD, Chief Scientific Officer of Emulate, about the rise of organ-on-a-chip technology. In the third article, DDW Editor Reece Armstrong speaks to Benedikt Nilges, Head of Technology and Data Analytics at OMAPiX about spatial biology's use in drug discovery and bettering our understanding of disease.
In this episode, Logan is joined by Zach Weinberg (Co-Founder/CEO @ Curie.Bio) and Derek Thompson (writer at The Atlantic) for a candid discussion on the state of U.S. healthcare and scientific progress. They unpack what went right, and wrong, with COVID vaccine policy, the public backlash against mRNA technology, and the ripple effects on trust in science. The conversation also dives into the real reasons behind NIH budget cuts, the economics of drug discovery, and the business incentives in medical R&D. It's a sharp, thought-provoking look at the intersection of policy, innovation, and public perception. (00:00) Introduction to Drug Pricing in the US (00:23) Broad Healthcare Topics and Open-Ended Discussion (02:37) COVID-19 Vaccines: Successes and Public Perception (06:21) The Evolution of COVID-19 and Vaccine Efficacy (07:59) Public Policy and Vaccine Mandates (13:10) Impact of School Closures and Public Sentiment (19:23) NIH Funding and the Importance of Basic Research (25:04) Challenges in Science Funding and Public Perception (35:19) Government vs. Private Investment in Science (36:40) Operation Warp Speed: A Case Study (39:07) Antibiotic Resistance Crisis (43:22) The Drug Pricing Debate (44:05) Challenges in Drug Discovery (54:06) Regulatory Hurdles in Medical R&D (58:06) The Future of Drug Development (01:04:19) Concluding Thoughts Executive Producer: Rashad Assir Producer: Leah Clapper Mixing and editing: Justin Hrabovsky Check out Unsupervised Learning, Redpoint's AI Podcast: https://www.youtube.com/@UCUl-s_Vp-Kkk_XVyDylNwLA
Unlock faster, smarter drug repurposing with open-source data that arms clinicians and researchers with actionable insights. This discussion explores how cutting-edge AI and knowledge graphs are transforming access to potential therapies by ranking 4,000 approved drugs against thousands of diseases - all in record time. Host Dr. Sanjay Juneja speaks with Dr. David Fajgenbaum, Co-founder of Every Cure, to reveal how their platform delivers 75 million computed drug-disease scores directly into the hands of healthcare providers worldwide. Learn how this approach accelerates clinical decision-making, supports evidence-based research, and breaks down barriers to innovative care strategies.
What happens when decades of lab expertise meet cutting-edge AI? In this interview, Dr. Jennifer Bath, President and CEO of ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), talks about how her team is using advanced science and artificial intelligence to develop safer, faster, and more effective antibody-based medicines. With over 3,000 antibody discovery programs completed, they are transforming the future of drug discovery—cutting time, costs, and risks in the development process. Discover how decades of hands-on lab experience and innovative AI tools are helping identify the best drug candidates faster than ever before.Learn more about ImmunoPrecise Antibodies: https://www.ipatherapeutics.com/Watch the full YouTube interview here: https://youtu.be/mE9mDa7uGTsAnd follow us to stay updated: https://www.youtube.com/@GlobalOneMedia?sub_confirmation=1
This is the latest episode of the free DDW narrated podcast, titled “Where are scientists making waves in drug discovery?”, which covers three articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “How pharma is targeting advances in Alzheimer's treatments”, “The start-up disrupting the field of women's reproductive health” and “India: Why is the country ramping up drug discovery research?” Cognition Therapeutics recently completed the enrolment of its Phase II SEQUEL trial for patients with mild-to-moderate Alzheimer's disease. The focus of the trial is to test Cognition Therapeutics' experimental drug, CT1812 for patients with dementia with Lewy Bodies and dry age-related macular degeneration. In the first article, Reece Armstrong speaks to Lisa Ricciardi, CEO of Cognition Therapeutics, to learn about what the company hopes to achieve with CT1812. In the second article, DDW's Diana Spencer speaks to Alok Javali, CSO of dawn-bio, a new addition to BioInnovation Institute's (BII) Venture Lab acceleration programme, about the lack of innovation in women's reproductive health and the company's plans to fill the vacuum. In the third article, I take a deeper look into why India is ramping up drug discovery research, and explores the country's innovation hubs of interest.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Tomasz Kostriezewski, CSO at CN Bio, about single organ-on-a-chip technology and multi-organ microphysiological systems (MPS), as well as accelerating drug discovery pipelines with these new alternative methodologies (NAMs). Clinical trial success rates are very low, with up to 95% not succeeding, and a wide range of disease states remains untreated. What NAMs permit is a screening of new drugs, of whatever entity – chemical or biological – to better predict how they will behave when put into a patient, says Kostriezewski. From metabolic to neurological diseases, as well as oncological – the applicability of organ-on-a-chip technologies is wide ranging, and regulators have been taking a more active role in trying to understand their role and value, and thereby validate their contextual usage at a future point. Nonetheless, already data is accepted today using this new approach, explains Kostriezewski, providing further insights on the landscape as market adoption continues to grow globally. You can listen to episode 174a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your other podcasts!
Martin Brenner, CEO and Chief Scientific Officer of iBio, is focused on the untapped potential of therapeutic antibodies for obesity and cardiometabolic diseases. Leveraging AI and machine learning, iBio is streamlining the antibody discovery and optimization process and addressing the need for more complex antibody mechanisms of action. Their lead candidate, iBio 600, is an anti-myostatin antibody designed to address the side effects of muscle mass and bone density loss associated with current GLP-1 therapies. Martin explains, "We can separate this into multiple areas. First of all, there's a predictive model that suggests that there are 5,000 different targets related to disease out there. So, there are 5,000 different possibilities to make medicines. All of the currently approved antibodies target only 92 targets. Even worse, 40% of approved antibodies only target about 10. So you can imagine there's a huge untapped potential of novel targets for which antibodies could be used. The problem is that the technologies must keep up with this to open that novel target space. That is problem number one." "So, as you know, AI has gotten a little bit of a bad reputation over the last few years, and there was a huge hype about this, and I want to be very clear about this. It takes more than 10,000 steps to make a medicine. At iBio, we enable three of these steps with generative AI. So, that does not make us an AI company. That does not make our molecules AI drugs. What it does is it actually makes it possible for us to create medicines that we couldn't do before. So, the way we use AI at iBio is multiplefold. First, we start our discovery process with the epitope steering engine. You have to imagine that drug targets are massive proteins, and only very small regions on these proteins have a biological function. So you want to get your antibody exactly to those regions that cause a biological function." #iBio #DrugDiscovery #MedAI #Obesity #GLP1 #CardioMetabolicDiseases #Antibodies #AntibodyTherapies #Myostatin iBioinc.com Download the transcript here
Martin Brenner, CEO and Chief Scientific Officer of iBio, is focused on the untapped potential of therapeutic antibodies for obesity and cardiometabolic diseases. Leveraging AI and machine learning, iBio is streamlining the antibody discovery and optimization process and addressing the need for more complex antibody mechanisms of action. Their lead candidate, iBio 600, is an anti-myostatin antibody designed to address the side effects of muscle mass and bone density loss associated with current GLP-1 therapies. Martin explains, "We can separate this into multiple areas. First of all, there's a predictive model that suggests that there are 5,000 different targets related to disease out there. So, there are 5,000 different possibilities to make medicines. All of the currently approved antibodies target only 92 targets. Even worse, 40% of approved antibodies only target about 10. So you can imagine there's a huge untapped potential of novel targets for which antibodies could be used. The problem is that the technologies must keep up with this to open that novel target space. That is problem number one." "So, as you know, AI has gotten a little bit of a bad reputation over the last few years, and there was a huge hype about this, and I want to be very clear about this. It takes more than 10,000 steps to make a medicine. At iBio, we enable three of these steps with generative AI. So, that does not make us an AI company. That does not make our molecules AI drugs. What it does is it actually makes it possible for us to create medicines that we couldn't do before. So, the way we use AI at iBio is multiplefold. First, we start our discovery process with the epitope steering engine. You have to imagine that drug targets are massive proteins, and only very small regions on these proteins have a biological function. So you want to get your antibody exactly to those regions that cause a biological function." #iBio #DrugDiscovery #MedAI #Obesity #GLP1 #CardioMetabolicDiseases #Antibodies #AntibodyTherapies #Myostatin iBioinc.com Listen to the podcast here
Biotech Bytes: Conversations with Biotechnology / Pharmaceutical IT Leaders
The Future of AI in Pharma & Biotech Research #aiinbiotech #pharmaresearch #drugdiscovery AI is fundamentally changing the way biotech and pharmaceutical research happens. From analyzing vast datasets to accelerating drug discovery, AI-powered solutions are making labs smarter, faster, and more efficient. But how does it actually work? Please visit our website to get more information: https://swangroup.net/ In this episode, I sit with Liran Belenzon, CEO of BenchSci, to explore how AI reshapes pharmaceutical research. We discuss:✅ The biggest challenges of working with scientific data✅ Why big pharma companies prefer AI-powered platforms over in-house solutions✅ How multimodal AI enhances lab efficiency and accelerates drug developmentLiran also shares his journey from being an MBA student to leading a company that works with 12 of the world's top 20 pharma companies. If you're curious about the intersection of AI, biotech, and research, this episode is a must-watch. Let's talk about the future of AI in biotech. What excites you the most? Let me know in the comments. Links from this episode:✅ Get to know more about Liran Belenzon: https://www.linkedin.com/in/liranbelenzon ✅ Learn more about BenchSci: https://www.benchsci.com ✅ Follow BenchSci for updates on AI in biotech: https://ca.linkedin.com/company/benchsci
This is the latest episode of the free DDW narrated podcast, titled “Innovation enabled by new drug discovery technologies”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Accelerating biotherapy and personalised medicine with long DNA” and “The microbiome in precision medicine”. In the first article, Matt Hill, Founder and CEO of Elegen writes about the importance of innovation in DNA synthesis to address critical bottlenecks in biotherapy development. In the second article, Katie Gillette, Senior Project Leader, Eliza French, Analyst, and Graham Friedman, Analyst, DeciBio, provide an industry overview of the role of the microbiome in precision medicine, and its interplay with research tools, diagnostics, and therapeutic development.
"I was born and raised in a developing country. I was born and raised in Pakistan. And it's very interesting when you're born in a developing country. That's your world. Right? That's all you know." In this episode of The Biotech Startups Podcast, we delve into Rabia Khan's remarkable journey from her childhood in Pakistan to founding Serna Bio, an AI-enabled drug discovery company. Rabia shares how her early experiences in a developing country, her aunt's battle with schizophrenia, and the sequencing of the human genome in 2000 sparked her passion for genetics and healthcare. She recounts how her career options were either medicine or engineering, setting her on a path that would eventually lead to pioneering work at the intersection of AI and biotechnology. Rabia describes her transition to McGill University in Montreal, facing the shock of -40°C weather with only a leather jacket while navigating life as an international student with no support system. Despite these challenges, she pursued dual interests in biology and economics, finding her first research opportunity in a schizophrenia lab where she started by pipetting water and washing dishes.
In this episode of Crazy Wisdom, Stewart Alsop speaks with German Jurado about the strange loop between computation and biology, the emergence of reasoning in AI models, and what it means to "stand on the shoulders" of evolutionary systems. They talk about CRISPR not just as a gene-editing tool, but as a memory architecture encoded in bacterial immunity; they question whether LLMs are reasoning or just mimicking it; and they explore how scientists navigate the unknown with a kind of embodied intuition. For more about German's work, you can connect with him through email at germanjurado7@gmail.com.Check out this GPT we trained on the conversation!Timestamps00:00 - Stewart introduces German Jurado and opens with a reflection on how biology intersects with multiple disciplines—physics, chemistry, computation.05:00 - They explore the nature of life's interaction with matter, touching on how biology is about the interface between organic systems and the material world.10:00 - German explains how bioinformatics emerged to handle the complexity of modern biology, especially in genomics, and how it spans structural biology, systems biology, and more.15:00 - Introduction of AI into the scientific process—how models are being used in drug discovery and to represent biological processes with increasing fidelity.20:00 - Stewart and German talk about using LLMs like GPT to read and interpret dense scientific literature, changing the pace and style of research.25:00 - The conversation turns to societal implications—how these tools might influence institutions, and the decentralization of expertise.30:00 - Competitive dynamics between AI labs, the scaling of context windows, and speculation on where the frontier is heading.35:00 - Stewart reflects on English as the dominant language of science and the implications for access and translation of knowledge.40:00 - Historical thread: they discuss the Republic of Letters, how the structure of knowledge-sharing has evolved, and what AI might do to that structure.45:00 - Wrap-up thoughts on reasoning, intuition, and the idea of scientists as co-evolving participants in both natural and artificial systems.50:00 - Final reflections and thank-yous, German shares where to find more of his thinking, and Stewart closes the loop on the conversation.Key InsightsCRISPR as a memory system – Rather than viewing CRISPR solely as a gene-editing tool, German Jurado frames it as a memory architecture—an evolved mechanism through which bacteria store fragments of viral DNA as a kind of immune memory. This perspective shifts CRISPR into a broader conceptual space, where memory is not just cognitive but deeply biological.AI models as pattern recognizers, not yet reasoners – While large language models can mimic reasoning impressively, Jurado suggests they primarily excel at statistical pattern matching. The distinction between reasoning and simulation becomes central, raising the question: are these systems truly thinking, or just very good at appearing to?The loop between computation and biology – One of the core themes is the strange feedback loop where biology inspires computational models (like neural networks), and those models in turn are used to probe and understand biological systems. It's a recursive relationship that's accelerating scientific insight but also complicating our definitions of intelligence and understanding.Scientific discovery as embodied and intuitive – Jurado highlights that real science often begins in the gut, in a kind of embodied intuition before it becomes formalized. This challenges the myth of science as purely rational or step-by-step and instead suggests that hunches, sensory experience, and emotional resonance play a crucial role.Proteins as computational objects – Proteins aren't just biochemical entities—they're shaped by information. Their structure, function, and folding dynamics can be seen as computations, and tools like AlphaFold are beginning to unpack that informational complexity in ways that blur the line between physics and code.Human alignment is messier than AI alignment – While AI alignment gets a lot of attention, Jurado points out that human alignment—between scientists, institutions, and across cultures—is historically chaotic. This reframes the AI alignment debate in a broader evolutionary and historical context, questioning whether we're holding machines to stricter standards than ourselves.Standing on the shoulders of evolutionary processes – Evolution is not just a backdrop but an active epistemic force. Jurado sees scientists as participants in a much older system of experimentation and iteration—evolution itself. In this view, we're not just designing models; we're being shaped by them, in a co-evolution of tools and understanding.
Dr. Jonathan Usuka, CEO of Sapient, uses insights about proteomics and metabolomics to provide deep molecular characterization of diseases from a single sample to support drug discovery, development, and approval. The company's unique dataset combines real-world data with longitudinal molecular profiling of tens of thousands of samples across different diseases, ethnicities, genders, and ages. By measuring proteins and metabolites, this data and insights engine helps pharmaceutical companies gain a significantly more comprehensive view of the molecular basis of disease, better understand drug targets, and predict potential drug outcomes and safety. Jonathan explains, "We support drug discovery and drug development, and a couple of things are going on in the industry right now in discovery and development. One is the overall pharma landscape of how a drug gets approved. That's been fairly static since the 1970s with the creation of the FDA. So clinical trials are well established, but the structure of it was based around not knowing much about the underlying drug target that your drug is interacting with. Since then, they've tightened up the requirements around mechanisms of action, but mostly, the process itself is almost protein agnostic in terms of the development process and how the drug interacts with patients." "So what we do, what has happened recently, is a revolution in understanding the molecular basis of disease and how the therapeutics interact with it at a molecular level. We support pharmaceutical companies in understanding the safety and the efficacy and being able to predict how their therapies will do in the clinic, and then really understanding a lot more about the available drug targets, which expands the arsenal of ways to fight disease." "At Sapient, we don't just identify dynamic biomarkers, biomarkers that change with disease or change in response to therapy. We also give a lot of context about those biomarkers. We also say where we have seen those biomarkers occur and how they have changed in response to other therapies, disease conditions, and immunological responses. So, a pharma company can see better what it's getting into when it invests in a dynamic biomarker." #SapientBio #Multiomics #Proteomics #Metabotomics #DarkProteome #BeyondtheGenome #Plasmaproteomics #Biomarkers sapient.bio Download the transcript here
Dr. Jonathan Usuka, CEO of Sapient, uses insights about proteomics and metabolomics to provide deep molecular characterization of diseases from a single sample to support drug discovery, development, and approval. The company's unique dataset combines real-world data with longitudinal molecular profiling of tens of thousands of samples across different diseases, ethnicities, genders, and ages. By measuring proteins and metabolites, this data and insights engine helps pharmaceutical companies gain a significantly more comprehensive view of the molecular basis of disease, better understand drug targets, and predict potential drug outcomes and safety. Jonathan explains, "We support drug discovery and drug development, and a couple of things are going on in the industry right now in discovery and development. One is the overall pharma landscape of how a drug gets approved. That's been fairly static since the 1970s with the creation of the FDA. So clinical trials are well established, but the structure of it was based around not knowing much about the underlying drug target that your drug is interacting with. Since then, they've tightened up the requirements around mechanisms of action, but mostly, the process itself is almost protein agnostic in terms of the development process and how the drug interacts with patients." "So what we do, what has happened recently, is a revolution in understanding the molecular basis of disease and how the therapeutics interact with it at a molecular level. We support pharmaceutical companies in understanding the safety and the efficacy and being able to predict how their therapies will do in the clinic, and then really understanding a lot more about the available drug targets, which expands the arsenal of ways to fight disease." "At Sapient, we don't just identify dynamic biomarkers, biomarkers that change with disease or change in response to therapy. We also give a lot of context about those biomarkers. We also say where we have seen those biomarkers occur and how they have changed in response to other therapies, disease conditions, and immunological responses. So, a pharma company can see better what it's getting into when it invests in a dynamic biomarker." #SapientBio #Multiomics #Proteomics #Metabotomics #DarkProteome #BeyondtheGenome #Plasmaproteomics #Biomarkers sapient.bio Listen to the podcast here
OpenAI has successfully raised $40 billion in what is believed to be the largest private technology funding round ever, boosting its valuation to $300 billion. This funding round was predominantly led by the Japanese investment firm SoftBank, which has now surpassed Microsoft as OpenAI's largest investor. Despite the impressive growth in revenue and user base, OpenAI continues to face challenges in achieving profitability, as it invests heavily in infrastructure and user acquisition. The company has announced plans to release its first open-weight language model since 2019, marking a strategic shift to adapt to competitive pressures from open-source alternatives.The podcast also highlights significant advancements in AI applications across various sectors. Researchers are leveraging AI to accelerate drug repurposing, enabling faster exploration of treatment options for patients with limited choices. American Express has integrated AI into its internal IT support, achieving a remarkable reduction in IT escalations and enhancing travel assistance for its elite customers. These examples illustrate the potential of AI to deliver tangible business value and improve operational efficiency.However, the integration of AI is not without its challenges. Bloomberg News has faced difficulties in generating accurate AI summaries for articles, leading to corrections and concerns about the reliability of AI-generated content. This underscores the importance of maintaining quality control and human oversight in AI applications, particularly in fields like journalism where accuracy is paramount.The episode concludes with a discussion on trends towards simplifying complex processes in business. Innovations such as rapid business valuation tools, enhanced customer communication through Rich Communication Services, and streamlined cyber insurance solutions reflect a broader movement to improve efficiency and accessibility in various industries. These developments highlight the ongoing evolution of technology and its impact on business operations, emphasizing the need for strategic implementation of AI and other technological advancements. Three things to know today 00:00 OpenAI's Rollercoaster Ride: Big Money, Open Models, and Profit Puzzles06:29 AI Wins and Woes: Curing Disease, Solving Problems, and Sometimes Missing the Mark10:41 MSPs Get a Boost: Faster Insights, Smoother Communication, and Insurance Made Easy Supported by: https://getnerdio.com/nerdio-manager-for-msp/ Join Dave April 22nd to learn about Marketing in the AI Era. Signup here: https://hubs.la/Q03dwWqg0 All our Sponsors: https://businessof.tech/sponsors/ Do you want the show on your podcast app or the written versions of the stories? Subscribe to the Business of Tech: https://www.businessof.tech/subscribe/Looking for a link from the stories? The entire script of the show, with links to articles, are posted in each story on https://www.businessof.tech/ Support the show on Patreon: https://patreon.com/mspradio/ Want to be a guest on Business of Tech: Daily 10-Minute IT Services Insights? Send Dave Sobel a message on PodMatch, here: https://www.podmatch.com/hostdetailpreview/businessoftech Want our stuff? Cool Merch? Wear “Why Do We Care?” - Visit https://mspradio.myspreadshop.com Follow us on:LinkedIn: https://www.linkedin.com/company/28908079/YouTube: https://youtube.com/mspradio/Facebook: https://www.facebook.com/mspradionews/Instagram: https://www.instagram.com/mspradio/TikTok: https://www.tiktok.com/@businessoftechBluesky: https://bsky.app/profile/businessof.tech
How is the pharmaceutical industry evolving to meet the world's biggest health challenges? In this episode, Nicolai Tangen sits down with Emma Walmsley, CEO of GSK, for an insightful conversation about the future of pharmaceuticals. They discuss GSK's latest advances in cancer treatments, HIV therapies, and respiratory medicine, as well as the role of AI in speeding up drug discovery. Emma also shares her thoughts on navigating change, transforming company culture, and the role of curiosity in staying motivated. Tune in!In Good Company is hosted by Nicolai Tangen, CEO of Norges Bank Investment Management. New full episodes every Wednesday, and don't miss our Highlight episodes every Friday.The production team for this episode includes Isabelle Karlsson and PLAN-B's Niklas Figenschau Johansen, Sebastian Langvik-Hansen and Pål Huuse. Background research was conducted by Isabelle Karlsson.Watch the episode on YouTube: Norges Bank Investment Management - YouTubeWant to learn more about the fund? The fund | Norges Bank Investment Management (nbim.no)Follow Nicolai Tangen on LinkedIn: Nicolai Tangen | LinkedInFollow NBIM on LinkedIn: Norges Bank Investment Management: Administrator for bedriftsside | LinkedInFollow NBIM on Instagram: Explore Norges Bank Investment Management on Instagram Hosted on Acast. See acast.com/privacy for more information.
In episode 87 of The Weekly Bioanalysis podcast, John Perkins and Dawn Dufield preview the upcoming WRIB conference, where KCAS Bio and Sciex will both have strong representation through scientific presentations, panels, and business development efforts. Special guest, Rahul Baghla of Sciex, discusses the company's collaboration with KCAS Bio and introduces their high-throughput Echo technology, which uses acoustic ejection to improve speed and reduce carryover in early discovery assays. The conversation explores the evolution of mass spectrometry platforms, highlighting the robustness and sensitivity of Sciex's 7500+ system and the increasing role of AI in streamlining data analysis. Dawn and John reflect on the challenges of adopting new technologies in regulated environments, emphasizing the balance between innovation and practical application.“The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they've learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio.KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.
Synopsis: How do you build a biotech company that disrupts drug discovery and delivers real impact? In this episode of Biotech 2050, host Rahul Chaturvedi speaks with Raj Devraj, President & CEO of Rectify Pharmaceuticals and Venture Partner at Atlas Venture. Raj shares his journey from big pharma to biotech entrepreneurship, the science behind Rectify's groundbreaking approach to drugging membrane proteins, and how his team is tackling rare hepatobiliary diseases with small-molecule therapies. He also dives deep into biotech innovation, smart capital strategy, M&A trends, and the power of hiring the right talent. Whether you're a biotech founder, investor, or science enthusiast, this episode is packed with insights on building, funding, and scaling a biotech startup in today's competitive landscape. Biography: Rajesh (Raj) Devraj, Ph.D., is President and Chief Executive Officer of Rectify Pharma and a Venture Partner at Atlas Venture. Throughout his career, he has been focused on creating and building groundbreaking biotech companies. Prior to Rectify, Raj co-founded Disarm Therapeutics with Atlas and served as its Chief Scientific Officer prior to its acquisition. Before Disarm, he served as Chief Scientific Officer of Atlas-founded Padlock Therapeutics. Prior to his tenure at Atlas, Raj served in senior executive roles at Euclises & Deciphera Pharmaceuticals and at Jubilant Life Sciences. In addition, Raj spent 14 years in positions of increasing responsibility with Pfizer Global R&D and the legacy Pharmacia and Searle companies. Raj also serves on the boards of directors for several biotech companies. Over a 25-year career in large pharma and biotech, Raj has led discovery, early clinical development, and strategic planning teams that have advanced multiple candidates into clinical trials for refractory cancers, autoimmune diseases, IPF, diabetic nephropathy, COPD, and pain. Raj received his B.S. in Pharmacy from the University of Mumbai, and Ph.D. in Medicinal Chemistry from Duquesne University.
In this episode, Dr. Rahul Gupta, President of GATC Health, joins Scott Becker to discuss how AI and machine learning are transforming the speed, cost, and success rates of drug development.
In this episode, Dr. Rahul Gupta, President of GATC Health, joins Scott Becker to discuss his groundbreaking work in drug discovery using artificial intelligence. Dr. Gupta shares insights from his career, including his leadership in combating the opioid crisis, and explains how AI and machine learning are transforming the speed, cost, and success rates of drug development.
Send us a textThe integration of AI into drug discovery has already led to groundbreaking advancements, uncovering patterns in vast datasets that were previously invisible to human researchers. Now, AI is set to revolutionize bioprocessing as well.In this episode of the Smart Biotech Scientist Podcast, Yossi Quint, founder and CEO of Ark, and David Brühlmann explore how AI and computational tools are reshaping bioprocess development. Yossi envisions a future where 90% of bioreactor experiments could be replaced by in silico simulations, dramatically accelerating time to market and increasing throughput.Key takeaways from the conversation with Yossi Quint:AI's Role in Drug Discovery & Bioprocessing: AI is already transforming drug discovery by identifying intricate patterns across millions of data points. Now, bioprocessing is undergoing a similar revolution, as computational tools simplify and streamline complex workflows.The Power of Hybrid Models: Yossi highlights the synergy between mechanistic models and AI-driven approaches, emphasizing how AI can fill gaps where traditional models struggle—especially in understanding complex cellular behaviors.Empowering Bioprocess Teams with AI: As AI accelerates drug discovery, bioprocessing must evolve to keep pace. Yossi discusses the importance of digital transformation in ensuring bioprocess teams can meet increasing demands and drive innovation forward.With AI-driven models, hybrid simulations, and increased digitization, the bioprocessing industry stands at the cusp of a new era. The convergence of data, science, and technology promises not only greater efficiency and accuracy but also a faster path to life-saving treatments for patients in need.If you want to learn more, here are a few standout conversations on AI's impact on bioprocessing with some incredible experts:Episodes 131-132: Combining AI and Biomanufacturing for Sustainable, Cost-Effective Therapeutics with Reza FarahaniEpisodes 115-116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy AgrestiEpisodes 111-112: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars BrandénEpisodes 107-108: From 1 Billion to 100: How AI is Cracking the Enzyme Discovery Code with David SchönauerEpisodes 95-96: AI in Bioprocess Development: The Game-Changer You Can't Ignore with Belma AlispahicConnect with Yossi Quint:LinkedIn: https://www.linkedin.com/in/yossi-quintArk: https://www.ark-biotech.comNext step:Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t
In this episode, Dr. Rahul Gupta, President of GATC Health, joins Scott Becker to discuss how AI and machine learning are transforming the speed, cost, and success rates of drug development.
The future of medicine is being shaped by technology, and few companies are pushing the boundaries like GSK. In this episode, I sit down with Christopher Austin, Head of Research Technologies at GSK, to explore how AI, data science, and cutting-edge digital capabilities are revolutionizing drug discovery and development. Chris shares how GSK is harnessing vast datasets, AI-driven insights, and genetic validation to speed up the identification of promising drug targets. We discuss how computational biology and machine learning are dramatically reducing the time it takes to develop new treatments—sometimes cutting discovery timelines in half. From selecting the right molecular designs to improving patient identification for clinical trials, technology is streamlining the entire R&D process, increasing success rates, and ultimately bringing life-saving medicines to patients faster. We also dive into the role of generative AI in modeling diseases, designing antibodies, and optimizing clinical trials. With AI now shaping everything from drug formulation to patient recruitment, we explore what this means for the future of medicine and the ethical considerations that come with such rapid advancements. How will AI-driven drug discovery change the pharmaceutical industry in the next decade? What challenges remain in integrating these new technologies into traditional research models? And what does all of this mean for patients and the future of healthcare? Tune in to hear how GSK is leading the charge in transforming medicine through technology.
Many in venture capital and biopharma are anointing artificial intelligence the savior of drug discovery—but what can AI actually do?In this eye-opening episode, Michael Marks sits down with Mike Nohaile, CEO of Prellis Biologics, to explore the hype versus reality in AI-enabled drug discovery. Mike details why, despite significant breakthroughs like AlphaFold and recent Nobel Prize win for computational protein design, fully AI-generated medicines still present challenges. He also discusses why we urgently need more effective medicines and details Prellis' unique system which combines laser printed human organoids and an externalized human immune system with AI, enabling the discovery of fully human antibodies. If you enjoy this episode, please subscribe and leave us a review on your favorite podcast platform. Sign up for our newsletter at techsurgepodcast.com for exclusive insights and updates on upcoming TechSurge Live Summits.Links:Explore Prellis Biologicshttps://prellisbio.com/Understand AlphaFold, DeepMind's AI model for predicting protein structureshttps://deepmind.google/alphafoldRead about the 2024 Nobel Prize in Chemistry https://www.nobelprize.org/prizes/chemistry/2024/press-release/
March 11, 2025 | In this episode of The Chain, host Andrew Buchanan, principal scientist at AstraZeneca, and Andreas Plückthun, professor and head of biochemistry at the University of Zurich, discuss AI/ML technologies in the antibody and protein engineering space. Plückthun shares his perspectives on what technologies show promise and success, why the definition of epitope is important when developing a drug, and what aspects he expects to improve in the ML field in the future.
Today's guest is Liran Belenzon, Co-founder and CEO of BenchSci. BenchSci is a global leader in AI solutions for preclinical R&D that helps decipher complex biomedical research using proprietary technology. Liran joins us to discuss how AI is transforming disease biology research, streamlining scientific workflows, and enabling better decision-making in pharmaceutical R&D. Liran shares insights into the biggest challenges facing drug discovery today, including the complexity of disease biology and the critical role AI plays in unraveling it. He breaks down how AI-driven knowledge graphs, ontological models, and multimodal AI systems are improving both the speed and quality of scientific research. This episode is sponsored by BenchSci. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1.
A recent study in the journal Nature unveiled new proteins that can neutralize the deadliest of snake venoms. They're “new” in that they aren't found in nature—they were created in a lab, dreamed up by AI.Using AI to discover, or design, the building blocks of drugs is a fast-growing area of research. Another team of scientists out of Philadelphia is using AI to discover new antibiotics by resurrecting long-lost molecules from extinct species like neanderthals and woolly mammoths.We know what you're thinking: It sounds too sci-fi to be true.Flora Lichtman talks with two pioneers in the field about how AI is supercharging drug discovery: Dr. César de la Fuente, bioengineer and presidential associate professor at the University of Pennsylvania in Philadelphia, and Nobel laureate Dr. David Baker, director of the Institute for Protein Design and professor at the University of Washington in Seattle.Transcripts for each segment will be available after the show airs on sciencefriday.com.For our Los Angeles listeners: We're working on a story about the toxins left behind by the fires and we want to hear from you. How is this affecting you? Are you worried about the air and water and soil? How are you approaching clean-up? And what questions do you have?Leave us a voicemail at 1-646-767-6532 or send us an email at scifri@sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.
Plus, Open AI CEO Sam Altman is sued by his sister. And Meta tests eBay crossovers on Facebook Marketplace. James Rundle hosts. Learn more about your ad choices. Visit megaphone.fm/adchoices